Literature DB >> 23330782

Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients.

Magalys Vitiello1, Antonella Tosti, Adriana Abuchar, Martin Zaiac, Francisco A Kerdel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23330782     DOI: 10.1111/j.1365-4632.2011.05320.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  8 in total

Review 1.  Small Molecules and Biologics in the Treatment of Nail Psoriasis.

Authors:  Dimitrios Rigopoulos; Anna Stathopoulou; Stamatios Gregoriou
Journal:  Skin Appendage Disord       Date:  2020-04-30

2.  Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations.

Authors:  Seungkeol Yang; Bo Ri Kim; Minsu Kim; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2021-03-08       Impact factor: 1.444

3.  Treatment of nail psoriasis: common concepts and new trends.

Authors:  Yasemin Oram; A Deniz Akkaya
Journal:  Dermatol Res Pract       Date:  2013-05-13

Review 4.  Nail psoriasis: the journey so far.

Authors:  Alka Dogra; Amanjot Kaur Arora
Journal:  Indian J Dermatol       Date:  2014-07       Impact factor: 1.494

Review 5.  Nail Psoriasis: A Review of Treatment Options.

Authors:  Marcel C Pasch
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 6.  Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

Authors:  Eckart Haneke
Journal:  Psoriasis (Auckl)       Date:  2017-10-16

Review 7.  Optimal management of nail disease in patients with psoriasis.

Authors:  Bianca Maria Piraccini; Michela Starace
Journal:  Psoriasis (Auckl)       Date:  2015-01-09

8.  Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a.

Authors:  Ka Lun Cheung; Rachael Jarrett; Sumithra Subramaniam; Maryam Salimi; Danuta Gutowska-Owsiak; Yi-Ling Chen; Clare Hardman; Luzheng Xue; Vincenzo Cerundolo; Graham Ogg
Journal:  J Exp Med       Date:  2016-09-26       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.